Cenofex Innovations is a medical device startup company delivering unique solutions from the research lab into the hands of those that need it.

 

Founded by a dynamic and passionate team, Cenofex Innovations is currently focused on the development of a medical device that will transform the treatment of lymphoedema.

 

We have a strong collaborative culture driven by a close knit and
diversely experienced team

 
TeamShot.jpg
 
 
Gho_profile3_2017.png
Weaver_profile_clr.png
102715-haasheadshots-1092 (2).jpg

Sheridan A. Gho, PhD

Founder and CEO

  • PhD in Biomechanics, University of Wollongong, Australia
  • 9+ years of experience in social and health research and biomechanics
  • Company lead in clinical research, customer relations and business management
  • NSW Health-Rosenman Institute Scholar 2016-17
  • Honorary Associate Fellow, University of Wollongong 2015-18

Michael R. Weaver, PhD

Founder and CTO

  • PhD in Medical Radiation Physics, University of Wollongong, Australia
  • 9+ years of experience in physics and mechatronic engineering
  • Company lead in technology, verification testing and product development
  • NSW Health-Rosenman Institute Scholar 2016-17
  • Honorary Associate Fellow, University of Wollongong 2015-18

Tri Luong, MBA

Head of Business and Finance

  • FT MBA, UC Berkeley Haas, USA. Economics BA, Stanford University, USA
  • 9+ years of experience in finance and operations, including 4 years in healthcare investment banking
  • Company lead in business management, finance and business strategy

 

 

We gained early validation through competitive fellowship funding

Cenofex Innovations founders, Dr. Sheridan Gho and Dr. Michael Weaver are the inaugural NSW Health - Rosenman Institute Scholars.

IMG_0993.jpg

Selected by the NSW State Government, Australia, to spend two years (2015-17) based at the UCSF-based QB3 Rosenman Institute in San Francisco, Sheridan and Michael founded Cenofex Innovations to develop and deliver a medical device that will transform the treatment of lymphoedema.
Through the extensive QB3 network, Sheridan and Michael developed key collaborations spanning technology, clinical, patient, and business sectors. The founders worked closely with the UCSF's academic clinicians to refine their device design inputs, and re-invented the device technology to better satisfy these inputs. Using the QB3 facilities, they refined their device prototype, designed and built verification tools for their innovative technology, and conducted initial testing in a laboratory environment.

In 2018, Michael and Sheridan returned to Australia where Cenofex Innovations continues to pursue the development and commercialisation of their medical device in NSW.

 

Connections & Collaborations

Cenofex Innovations is supported by a number of excellent business advisers, medical device developers, engineers, researchers and clinicians.